MN HF3756

Defines "covered insulin" as validly prescribed insulin drugs for treating diabetes, excluding products labeled only for intravenous infusion use

Exempts insulin products from program requirements if the wholesale acquisition cost is $8 or less per milliliter, adjusted annually for inflation

Exempts manufacturers with annual gross revenue of $2,000,000 or less from covered insulin sales in Minnesota from program requirements

Replaces terminology of "prescription insulin" with "covered insulin" throughout the insulin safety net program and manufacturer registration fee statutes

Repeals the requirement for the Department of Health to conduct program satisfaction surveys of individuals and pharmacies participating in the insulin safety net program